Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

InMed Pharmaceuticals  / Equity Bottom-Up

<div><div><div><ul><li>BayMedica continues impressive growth. As had already been signaled in an early disclosure filing in July, InMed’s BayMedica subsidiary delivered $2.3 million of revenue for the final quarter of its fiscal year ended June 30, 2023.</li><li>This represents 124% sequential revenue growth over the preceding quarter following sequential revenue growth of 46% and 120% recorded for 2QFY23 and 3QFY23, respectively.</li><li>The full fiscal year 2023 revenue total exceeded $4.1 million.</li></ul></div></div></div>

BayMedica continues impressive growth. As had already been signaled in an early disclosure filing in July, InMed’s BayMedica subsidiary delivered $2.3 million of revenue for the final quarter of its fiscal year ended June 30, 2023.This represents 124% sequential revenue growth over the preceding quarter following sequential revenue growth of 46% and 120% recorded for 2QFY23 and 3QFY23, respectively.The full fiscal year 2023 revenue total exceeded $4.1 million.

InMed Pharmaceuticals, Inc. - 4QFY23 Review; Progress on All Fronts